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Abstract
Background: The CvLPRIT study showed a trend for improved clinical outcomes in the complete revascularisation
(CR) group in those treated with an immediate, as opposed to staged in-hospital approach in patients with multivessel
coronary disease undergoing primary percutaneous intervention (PPCI). We aimed to assess infarct size and left ventricular
function in patients undergoing immediate compared with staged CR for multivessel disease at PPCI.
Methods: The Cardiovascular Magnetic Resonance (CMR) substudy of CvLPRIT was a multicentre, prospective,
randomized, open label, blinded endpoint trial in PPCI patients with multivessel disease. These data refer to a post-hoc
analysis in 93 patients randomized to the CR arm (63 immediate, 30 staged) who completed a pre-discharge CMR scan
(median 2 and 4 days respectively) after PPCI. The decision to stage non-IRA revascularization was at the discretion of
the treating interventional cardiologist.
Results: Patients treated with a staged approach had more visible thrombus (26/30 vs. 31/62, p = 0.001), higher SYNTAX
score in the IRA (9.5, 8–16 vs. 8.0, 5.5–11, p = 0.04) and a greater incidence of no-reflow (23.3 % vs. 1.6 % p < 0.001) than
those treated with immediate CR. After adjustment for confounders, staged patients had larger infarct size
(19.7 % [11.7–37.6] vs. 11.6 % [6.8–18.2] of LV Mass, p = 0.012) and lower ejection fraction (42.2 ± 10 % vs.
47.4 ± 9 %, p = 0.019) compared with immediate CR.
Conclusions: Of patients randomized to CR in the CMR substudy of CvLPRIT, those in whom the operator
chose to stage revascularization had larger infarct size and lower ejection fraction, which persisted after
adjusting for important covariates than those who underwent immediate CR. Prospective randomized trials
are needed to assess whether immediate CR results in better clinical outcomes than staged CR.
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Background
The management of multivessel coronary artery disease
in patients with ST-segment myocardial infarction at
primary percutaneous coronary intervention (PPCI) is
controversial (1). Registry data have suggested that a
staged complete revascularization (CR) strategy results
in better clinical outcomes than immediate CR at the
time of PCI. However two recent randomised, controlled
trials (2, 3) demonstrated reduced medium-term major
adverse cardiovascular event (MACE) rates compared
with infarct related artery (IRA)-only revascularization.
These findings have resulted in the withdrawal of the
American College of Cardiology Choosing Wisely advice
of not to undertake CR at the time of PPCI (4). In
addition we have shown that CR is not associated with
an increase in total infarct size assessed by in-patient
cardiovascular magnetic resonance (CMR), despite a
small increase in type 4a MI compared to an IRA-only
revascularization strategy (5).
There remains however no consensus on whether in-
hospital complete revascularisation should be staged
(staged CR) or undertaken immediately after PPCI (Im-
mediate CR). In the CvLPRIT study (3), there was a
trend for reduced clinical events (death/MI/heart failure)
in patients who had immediate (3.1 %) rather than
staged (11.9 %) CR.
The aim of this post hoc analysis of the CvLPRIT
CMR substudy (5) was to assess infarct size and LV
function in patients who underwent immediate com-
pared to staged CR, in order to gain insight into the
likely mechanisms to explain the differences in clinical
outcomes.
Methods
Study design
The study design and main results have been published
previously (3, 6). CvLPRIT CMR was a prespecified
substudy of a multicenter, prospective, randomized,
controlled, open- label, clinical trial with blinded CMR
endpoint analysis (PROBE design) conducted in 7 UK
centers between May 2011 and May 2014 (5). Inclusion
and exclusion criteria were as for the main trial with
absolute contraindications to CMR imaging as an
additional exclusion.
Patient recruitment and treatment
After verbal assent patients were randomized after
coronary angiography but before IRA PCI, to IRA-only
or in-hospital complete revascularization. If there were
no clinical contraindications, immediate CR was recom-
mended but the non-IRA procedure could be staged, at
the operator’s discretion, but completed during the index
admission. Reasons for staging revascularization were
not recorded. Recruitment is shown in Fig. 1. Ninety-
eight patients in the substudy were randomised to in-
hospital CR, of which 63 were performed immediately
and in 30 the procedure was staged. Five patients
crossed over into the IRA-only treatment arm.
Angiographic analysis
Pre and post-PPCI epicardial coronary flow was assessed
using Thrombolysis In Myocardial Infarction scoring (7).
Collateral flow to the IRA pre-PPCI was graded using
the Rentrop system (8). Quantitative Coronary Angiog-
raphy (QCA) was undertaken using QAngioXA v1.0 soft-
ware (Medis, Leiden, Netherlands). Myocardium at risk
was angiographically quantified using the Alberta Pro-
vincial Project for Outcome Assessment in Coronary
Heart Disease (APPROACH score) (9, 10).
CMR
The CMR methods have been described in detail previ-
ously (5). In brief, CMR was performed pre-discharge
and after any staged procedure and at 9 months (follow-
up CMR).
Pre-discharge CMR
After localisers and long axis cine images, complete
stacks of short axis images covering the entire left
ventricle (LV) were acquired with (1) T2w-STIR to de-
termine the area at risk, (2) cine images for LV volumes,
mass and ejection fraction and (3) late gadolinium
enhanced (LGE) images to determine infarct size and
MVO after administration of 0.2 mmol/kg of Magnevist
(Bayer, Leverkusen, Germany).
Follow-up CMR
Follow-up CMR was performed at 9 months (±4 weeks)
post-PPCI. The protocol for follow-up CMR was similar
to the pre-discharge scan, but with T2w-STIR imaging
omitted and assessment of reversible ischemia with first-
pass perfusion after pharmacological stress with adeno-
sine included.
CMR analysis
Analysis was performed as previously described by
physicians blinded to all clinical data including treat-
ment allocation at the University of Leicester core lab
(5). Briefly, infarct size was quantified on LGE imaging
using the Full-Width Half-Maximum technique (11).
On the pre-discharge CMR scan, ischaemic area-at-
risk (oedema) was assessed using Otsu’s Automated
Technique (12) and myocardial salvage index (MSI)
was calculated as the percentage of the area at risk
that was not infarcted on LGE (5). If infarction was
seen in >1 coronary territory in the pre-discharge
CMR, this was recorded as being in the IRA territory
(associated oedema and/or MVO) or the non-IRA
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territory with the consensus of three observers (JNK,
GPM, JPG). Non-IRA infarcts were additionally classi-
fied as likely to be acute or chronic (presence of wall
thinning and no oedema/MVO). Infarct size was
recorded for both IRA and non-IRA LGE and total
infarct size was the sum of all LGE. On the follow-up
CMR, perfusion images were visually assessed for
defects and reversible ischaemia burden calculated as
a percentage expression of the summed difference
score (13).
Clinical outcomes and follow-up
MACE comprised a composite of all-cause mortality,
recurrent MI, heart failure and ischemia-driven revascu-
larization. Secondary endpoints included cardiovascular
death and individual components of the primary end-
point. Safety endpoints comprised stroke, major bleeding
and contrast-induced nephropathy. Data were collected
by an independent clinical trials unit (Royal Brompton
Hospital, London) and events adjudicated by blinded
clinicians.
Statistical analysis
The primary outcome of the CMR substudy was infarct
size (expressed as % of LV mass) on pre-discharge CMR,
analysed on a log-transformed scale due to right skew.
This was adjusted for known baseline predictors of infarct
size (anterior MI, time to revascularization, diabetes, TIMI
flow pre-PPCI) and important baseline variables that
significantly differed between the two groups (TIMI flow
post-PPCI, SYNTAX score, dual antiplatelet therapy
choice, glycoprotein inhibitor/bivalirudin use for N-IRA
PCI) using generalized mixed models. Normally distrib-
uted continuous variables were expressed as mean ±
standard deviation and comparison was with student’s t-
tests. Non-normally distributed data were expressed as
median (25th–75th quartiles) and analysed using Mann-
Whitney testing. Categorical variables were compared
using Chi-squared testing. Clinical outcomes were
assessed using time-to-first event survival analysis (log-
rank test with right censoring). Kaplan-Meier curves were
plotted for the period of randomization to the occurrence
of the clinical outcomes and compared using log-rank test,
and Cox proportional hazard models were fitted to
estimate hazard ratios and 95 % confidence intervals for
treatment comparisons.
Results
Baseline characteristics
Baseline characteristics and comorbidities were closely
matched in the in-hospital staged and Immediate CR
subgroups and were similar to those in the overall
CvLPRIT study population (Table 1). Four patients in
the immediate CR group versus none in the staged
group had a history of non-STEMI and previous PCI.
Fig. 1 Consort diagram for patient recruitment. CONSORT diagram illustrating recruitment and patient flow. In the topmost green and red boxes
are the numbers of patients randomised to each treatment arm (intention to treat) and the number who subsequently received each treatment.
CR = complete revascularisation, IRA = infarct related artery; CMR = cardiovascular magnetic resonance
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Angiographic and PCI details
The median time to staged non-IRA PCI was 34.2 h
post-PPCI (IQR 24.8–48.9). There was increased visible
thrombus, subsequent thrombectomy catheter use, a
higher incidence of IRA no-reflow and reduced TIMI
grade post-PPCI in staged CR patients (Table 2). There
was a small but significant increase in CAD complexity
in the staged group (SYNTAX score 18.3 vs. 16, p =
0.021) involving the IRA (p = 0.043). The prevalence of
well collateralised IRA territory and LAD IRA were
similar in both groups. The angiographically derived
AAR on APPROACH score was similar in the groups.
Patients with right coronary artery IRA were more likely,
and those with circumflex IRA less likely, to have a
staged procedure. There was less glycoprotein IIb/IIIa
inhibitor and bivalirudin use during the non-IRA PCI in
the staged compared to the immediate CR group. When
the staged and PPCI procedures were added, there was
significantly increased cumulative screening time,
contrast dose, number of stents (non-IRA PCI and total
number of stents) and total procedure lengths in staged
versus immediate CR (Table 2).
CMR data
Pre-discharge CMR
Results are displayed in Table 3. Pre-discharge CMR
was undertaken later in staged CR patients than in
those undergoing immediate CR (4.1 [2.7–5.4] days
post PPCI vs. 2.3 days [1.7–3.2], p < 0.001). LV ejection
fraction was significantly lower in staged patients.
Median total infarct size was significantly greater in
staged patients (19.7 % (11.7–37.6) vs. 11.6 % (6.8–
18.2) LVM, p = 0.016) and this was associated with an
increase in peak creatine kinase of borderline statis-
tical significance. When corrected for important co-
variates, infarct size remained greater (p = 0.012). In
22 patients (24 %), area at risk could not be quantified.
MSI was lower in staged CR patients and there was a
greater extent of MVO (p = 0.032).
The prevalence of non-IRA territory infarcts in staged pa-
tients was almost three-fold that of the Immediate CR
group (40 % vs. 14 %, p = 0.006), including when only acute
non-IRA infarcts were included (30 % vs. 11 %, p = 0.024).
Examples are shown in Fig. 2 and the location, size of
infarct, expected coronary artery territory and additional
non-IRA PCI are shown in Additional file 1: Table S1.
Non-IRA territory infarcts varied considerably in size from
0.1 to 11.9 % of LV mass and averaged 3.7 % (immediate)
and 2.9 % (staged) of LV mass. Two patients (3 %) in the
immediate and three (10 %) in the staged CR group had
chronic non-IRA infarcts (evidenced by wall thinning).
Excluding these patients from the analysis did not signifi-
cantly alter the results (Additional file 1: Table S2).
Follow-up CMR
Results are shown in Table 3. Fifty-three patients in the im-
mediate group and 26 in the staged group underwent
follow-up CMR. There were no differences in baseline
Table 1 Baseline characteristics of main CvLPRIT trial and immediate versus staged in-hospital complete revascularisation CMR sub-
study participants
Variable CvLPRIT cohort
(n = 296)
Immediate CR
(n = 63)
Staged CR
(n = 30)
p
Age (y) 64.9 ± 11.6 63.0 ± 11.6 65.0 ± 10.3 0.42
Male sex (%) 240/296 (81.1) 55 (87.3) 28 (93.3) 0.38
BMI (kg/m2) 27.3 (24.4–30.2) 27.7 ± 4.5 27.6 ± 4.1 0.95
Heart rate (beats per minute) 74.4 ± 17.6 71.9 ± 16.4 73.5 ± 18.0 0.68
Systolic BP (mmHg) 137.6 ± 27.1 132.6 ± 26.8 140.0 ± 27.7 0.23
Anterior infarct (%) 106 (35.6) 21 (33.3) 11 (36.7) 0.75
eGFR (ml/min/1.73) 95.74 ± 34.7 96.1 ± 30.2 101.5 ± 41.0 0.49
Hypertension (%) 105/287 (36.6) 24 (38.1) 10 (33.3) 0.66
Hypercholesterolemia (%) 75/287 (26.1) 16 (25.4) 12 (40.0) 0.15
Diabetes Mellitus (%) 39/287 (13.6) 11 (17.5) 4 (13.3) 0.61
Current smoker (%) 87/285 (30.5) 23 (36.5) 10 (33.3) 0.77
Previous MI (%) 12/287 (4.2) 4 (6.3) 0 (0.0) 0.16
Previous PCI (%) 9/287 (3.1) 4 (6.3) 0 (0.0) 0.16
Anti-anginal medication (B/N) 54/287 (18.8) 8/63 (12.7) 5/29 (17.2) 0.56
Killip Class II-III (%) 24/286 (8.4) 4 (6.3) 2 (6.7) 0.95
Abbreviations: CR complete revascularization, BME black or minority ethnicity, BMI body mass index, eGFR estimated glomerular filtration rate, CK creatine kinase,
MI myocardial infarction, PCI percutaneous coronary intervention
Anti-anginal medication (B/N) = beta-blocker or nitrate at admission
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characteristics or pre-discharge CMR findings between
those who did and did not attend the follow-up CMR (data
not shown). Total infarct size remained greater in staged
CR patients (13.5 % vs. 5.7 %, p = 0.004, corrected p =
0.044). Reversible perfusion defects were seen in 20 % of
the immediate and 27 % of the staged patients but the over-
all ischemic burden was small (2.6 ± 6.9 and 5.2 ± 12.1 % re-
spectively) and not significantly different between groups.
Clinical outcomes
Discharge medication was similar between groups
(Additional file 1: Table S3). Median follow-up was
365 days (immediate CR 365 days, staged CR 361 days,
p = 0.75). Length of inpatient stay was longer in staged
CR (4.2 ± 3.2 vs. 3.1 ± 1.9, p = 0.002) compared to
immediate CR. The overall MACE rate was low
(6.5 %) at 1 year. The incidence of in-hospital clinical
Table 2 Periprocedural details in the immediate and staged in-hospital complete revascularisation groups
Variable Immediate CR (n = 63) Staged CR (n = 30) p
Symptom to PCI time (min) 180 (128–307) 203 (152–296) 0.95
Radial access (%) 50 (80.6) 27 (90.0) 0.26
Aspirin 62 (98.4) 30 (100) 0.49
Second antiplatelet agent (n, %) 63 (100) 30 (100) 1.00
GPI during PPCI (n, %) 20 (31.7) 11/29 (37.9) 0.56
Bivalirudin during PPCI (n, %) 32 (53.3) 17/27 (63.0) 0.40
Infarct related artery:
Left Anterior Descending (n, %) 20 (31.7) 11 (36.7) 0.64
Right Coronary (n, %) 24 (38.1) 19 (63.3) 0.022
Circumflex (n, %) 19 (30.2) 0 (0) 0.001
Visible thrombus (n, %) 31/62 (50.0) 26/30 (86.7) 0.001
Thrombectomy catheter (%) 39/63 (61.9) 26/30 (86.7) 0.015
Vessels with ≥75 % stenosis (n) 1.5 ± 0.6 1.6 ± 0.6 0.82
Stenosis in non-IRA lesions (%) 73.4 72.9 0.85
SYNTAX score (total) 16 (12–21.5) 18.3 (15–26) 0.021
SYNTAX score (IRA) 8 (5.5–11) 9.5 (8–16) 0.043
SYNTAX score (NIRAs) 6 (4–9) 7 (4.8–12) 0.24
Rentrop grade 0 (0–1) 1 (0–1) 0.35
Rentrop grade 2–3 pre PCI (n, %) 7/63 (11.1) 3/30 (10.0) 0.87
APPROACH area at risk (%) 26.0 ± 11.7 29.2 ± 10.8 0.21
TIMI grade pre PCI 0 (0–1) 0 (0–0) 0.47
TIMI grade post PCI 3 (3–3),
2.92 ± 0.4
3 (3–3),
2.77 ± 0.5
0.023
IRA no-reflow (n, %) 1 (1.6) 7 (23.3) <0.001
GPI at NIRA PCI (n, %) 20 (31.7) 4 (7.7) 0.06
Bivalirudin during NIRA PCI (n, %) 32/60 (53.3) 3/28 (10.7) <0.001
GPI or Bivalirudin at NIRA PCI (n, %) 50/60 (87.7) 7/28 (25.0) <0.001
Total Contrast dose (ml) 295 (213–350) 390 (266–555) 0.002
Total Screening time (min) 15.5 (12–21) 21 (17–43.3) 0.001
Total Procedure length (IRA + NIRA, min) 58 (38.5–72.8) 91 (67–154.3) <0.001
IRA PCI procedure length (min) 53 (35–70.5) 55 (37.5–81.3) 0.08
Total number of stents (n) 2.8 ± 1.1 3.4 ± 1.4 0.034
Number of stents in IRA (n) 1.3 ± 0.6 1.6 ± 0.8 0.09
Number of stents in NIRAs (n) 1.5 ± 0.8 1.8 ± 1.0 0.026
Data presented as n/N (%), mean ± SD or median (IQR)
Abbreviations: CR complete revascularization, IRA infarct related artery, PCI percutaneous coronary intervention, GPI glycoprotein IIa/IIIb inhibitor, QCA quantitative
coronary angiography, TIMI thrombolysis in myocardial infarction
Khan et al. Journal of Cardiovascular Magnetic Resonance  (2016) 18:85 Page 5 of 9
events, overall MACE and individual components
were similar in the treatment arms (Additional file 1:
Table S4), apart from a higher frequency of major
bleeds in staged CR (10.0 % vs. 0.0 %, p = 0.011).
Discussion
This post hoc analysis of patients in the CvLPRIT CMR
substudy is the first report of infarct size following
immediate and staged CR for multivessel disease at
PPCI. We have shown that patients in the CvLPRIT
study who were randomized to CR, and in whom experi-
enced interventional cardiologists chose to stage non-
IRA PCI, had more visible IRA thrombus, slightly but
significantly higher SYNTAX score, lower TIMI scores
and more no-flow after PPCI. These differences in base-
line angiographic and PPCI results were associated with
larger infarcts, less myocardial salvage and reduced ejec-
tion fraction compared to patients who had immediate
CR. It is important to highlight that patients in this ana-
lysis were not randomized to immediate or staged CR
and there were many differences in baseline characteris-
tics between the groups. Therefore, despite adjusting for
known baseline predictors of infarct size and other vari-
ables that significantly differed between the two groups,
the results are still likely to suffer from unknown biases
and we cannot conclude that staging results in larger
Table 3 Peak creatine kinase and pre-discharge and follow-up CMR data
Variable Immediate CR
(n = 63)
Staged CR
(n = 30)
p
Peak CK (IU/L) 939 (627–1567) 1508 (938–2280) 0.05
Pre-discharge CMR
Total Infarct Size (% LVM) 11.6 (6.8–18.2)
13.5 ± 11.4
19.7 (11.7–37.6)
22.6 ± 14.5
0.016
(0.012)*
Time from PPCI (days) 2.3 (1.7–3.2) 4.1 (2.7–5.4) <0.001
Infarct on LGE (%) 60 (95.2) 30 (100) 0.22
Patients with >1 acute infarct 7 (11.1) 9 (30.0) 0.024
IRA Infarct size (% LVM) 11.1 (5.4–17.4)
12.5 ± 10.0
19.1 (8.8–35.2)
20.9 ± 14.6
0.039
(0.05)*
Non-IRA Infarct size (% LVM) 0.9 ± 3.2 1.7 ± 3.6 0.11
(0.65)*
Total acute infarcts (% LVM) 11.6 (6.8–17.6)
13.0 ± 10.3
19.1 (10.2–37.1)
21.7 ± 14.8
0.006
(0.025)*
Area at risk (% LVM) 31.4 ± 12.5 33.1 ± 10.8 0.57
MSI§ (%) 61.7 (37.4–75.5) 35.1 (5.9–66.4) 0.008
(0.034)*
MVO present (n %) 34/63 (54.0) 21/30 (70.0) 0.14
MVO (% LVM) 0.07 (0.00–0.93) 0.44 (0.00–6.1) 0.032
(0.024)*
LVMI (g/m2) 52.5 (47.7–61.0) 51.5 (45.6–63.0) 0.55
LVEDVI (ml/m2) 89.9 (78.4–110.0) 89.7 (82.8–102.9) 0.43
LVEF (%) 47.4 ± 9.4 42.2 ± 10.2 0.019
Follow-up CMR n = 53 n = 26
LVMI (g/m2) 45.2 (38.8–52.3) 47.4 (40.9–51.6) 0.71
LVEDVI (ml/m2) 92.5 (80.5–105.5) 93.9 (83.3–113.6) 0.28
LVEF (%) 50.9 ± 9.4 46.7 ± 8.9 0.06
Infarct on LGE (n,%) 51 (96.2) 26 (100) 0.32
Patients with >1 infarct (%) 9 (17.0) 9 (34.6) 0.08
IS (% LVM) 5.7 (2.4–10.4) 13.5 (4.6–23.3) 0.004
(0.044)*
Data presented as n/N (%), mean ± SD or median (IQR)
Abbreviations: CR complete revascularization, IRA infarct related artery, LVMI left ventricular mass index, LVEDVI left ventricular end-diastolic volume index, LVEF
left ventricular ejection fraction, LGE late gadolinium enhancement, IS infarct size, MVO microvascular obstruction, MSI myocardial salvage index
§Analyzable oedema imaging available in 76 % of patients in both groups
*Adjusted for known predictors of IS (anterior MI, time to revascularization, diabetes, TIMI flow pre-PPCI) and important baseline variables significantly varying
between the two groups (TIMI flow post-PPCI, SYNTAX score, dual antiplatelet therapy choice, glycoprotein inhibitor/bivalirudin use for N-IRA PCI)
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infarcts than immediate CR. These data can therefore be
considered hypothesis-generating only, but warrant fur-
ther investigation in larger studies.
Infarct size, MVO and myocardial salvage
The lower total infarct size and MVO extent, higher MSI
and LV ejection fraction observed with immediate CR may
be due to a number of possible factors. There could be real
differences arising from treatment strategies; the staged
group may have been having larger infarcts and thirdly the
decision to stage the procedure, at least in some cases, may
have been as a direct result of poor technical success e.g.
no-reflow of the IRA. We think it is unlikely that staged pa-
tients were having larger infarcts at baseline as the time to
presentation, proportion having anterior MI, degree of col-
lateralization of the IRA and Killip Class were not signifi-
cantly different from the immediate CR group and
adjusting for these variables did not significantly alter the
results. In addition, the ischaemic area at risk was not sig-
nificantly different in the two groups. This was the case
both when quantified on CMR and on the angiographically
derived APPROACH score, which would negate any effect
of differing CMR timing. A significant effect of ischemic
preconditioning is also unlikely given the low prevalence of
anti-anginal medication use in both groups (14).
Immediate CR to non-IRA’s could theoretically
reduce infarct size by increasing collateral flow or by
improved blood flow to the watershed region of the
infarct (15). The severity of the non-IRA lesions (aver-
age stenosis diameter 73 % in both groups) also indi-
cates that these were likely to have been flow-limiting
stenoses. In support of a real effect of immediate CR is
the increase in MSI compared to staged patients.
However, and most importantly, differences in angio-
graphic and PPCI results most likely explain the
reductions in MSI and increased infarct size in the
staged v immediate CR groups. The staged group had
significantly more visible thrombus in the IRA (87 % v
50 %), subsequent thrombectomy catheter use and
significantly more no-reflow (23 % v 2 %) than the
immediate CR group. These factors are likely to be the
main reason for the increase in infarct size, reduced
salvage and decreased ejection fraction. We did not
prospectively record the operators’ reasons for staging
the non-IRA procedures in staged patients but we
think it is likely that a suboptimal result from the
PPCI and the presence of inferior rather than lateral
MI influenced the decision to stage the non-IRA PCI.
Non-IRA MI
A surprising finding in this study was that the frequency
of non-IRA MI detected by CMR was considerably
higher in the staged versus immediate CR groups. PCI
related MI (type 4a) are well recognized, (16, 17)
although of uncertain clinical significance. In elective
PCI patients up to 29 % (18) will have significant
increases in troponin and a similar proportion of
patients undergoing complex PCI will have evidence of
type 4a MI on CMR, even when pre-treated with clopi-
dogrel for >24 h and a glycoprotein IIb/IIIa inhibitor
periprocedurally (18). Excluding those patients with evi-
dence of chronic infarction, acute non-IRA MI was seen
in 30 % of the staged and only 11 % of the immediate
CR groups. Although these type 4a MI were relatively
infrequent and small (3.7 and 2.8 % of LV mass for
immediate and staged patients respectively) there was
Fig. 2 Examples of patients with >1 ‘acute’ MI on CMR. Late gadolinium enhanced short axis (top row) and long axis (bottom row). IRA-related
infarct; NIRA-related infarct(s). a (X511 Immediate CR): IRA (RCA) inferior infarct 19.1 % LVM, NIRA (LAD) anterior infarct 3.8 % LVM, total IS 22.9 %
LVM. b (X695 Immediate CR): IRA (RCA) inferior infarct 7.8 % LVM, NIRA (LAD) anteroseptal infarct 5.0 % LVM, total IS 12.8 % LVM. c (X757 Staged
CR): IRA (LAD) anteroseptal infarct 20.8 % LVM, NIRA (LCX) lateral infarct 0.6 % LVM, total IS 21.4 % LVM. d (X798 Staged CR): 3 acute infarcts, IRA
(LAD) anteroseptal infarct 35 % LVM, NIRA-1 (RCA) inferior infarct 0.7 % LVM, NIRA-2 (LCX) lateral infarct 2.0 % LVM, total IS 37.6 % LVM. IRA infarct
size and non-IRA PCI in Additional file 1: Table S1
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considerable variation in size. Revascularization related
injury accounting for 4 % of LV mass has been associ-
ated with a three-fold increase in MACE (19). Larger
randomized studies are required to confirm whether
staging CR results in more frequent non-IRA MI and
poorer outcomes than immediate CR.
The explanation for the increase in type 4a MI seen
with staged CR is likely to be related to greater number
of stents implanted in the non-IRA of the staged
patients and possibly the different use of adjunctive
medication at the time of the non-IRA PCI. Glycopro-
tein IIb/IIIa inhibitor (8 %) and bivalirudin (11 %) use
was low in the staged procedures compared to the
immediate CR group (32 and 53 % respectively), which
probably reflects clinicians concerns about bleeding with
a second in-patient procedure requiring additional vas-
cular access.
Clinical outcomes
The clinical event rate in both groups was similar (imme-
diate 6.3 % and staged 6.7 %) and lower than seen in the
main trial for those randomized to CR (10 %). The lack of
other significant differences between the two groups in
this post-hoc analysis with small numbers mean no
conclusions can be drawn. Immediate CR was associated
with a shorter inpatient stay of one night compared with
staged CR. This finding and the reduction in lab time with
second procedures may suggest that an immediate CR is
likely to be more cost effective than a staged strategy (20).
However these findings could simply be related to the fact
the staged patients had larger MI and although cost-
effectiveness will be assessed in the entire CVLPRIT
population, any differences between staged and immediate
CR would have to be confirmed in randomized trials
comparing these strategies. The increased frequency of
major bleeds with staged CR is likely secondary to the
need for two separate procedures and hence two arterial
punctures. However, due to the small numbers, this
should be confirmed in a larger study.
This is a post-hoc analysis and patients were not rando-
mised to immediate or staged CR. We did not systematic-
ally record the reasons for staging the procedure or use of
adjunctive medication, which is a significant limitation. The
marked differences in angiographic appearances at baseline,
and success following PPCI, are likely to contribute to the
observed differences in infarct size between the immediate
and staged CR groups. However statistical significance
persisted after correction for important baseline covariates.
Due to the small numbers of patients in this analysis,
propensity matching was not possible. The study was not
powered for clinical outcomes. Inevitably, patients who died
early or who were very ill following PPCI could not partici-
pate in the CMR study which likely explains why the
clinical event rates are lower than in the main study. The
pre-discharge CMR was undertaken later in staged patients
(day 4), which is likely to have resulted in a decrease in
infarct size and MVO extent compared with scanning at
day 2 (21). Hence, the observed differences in CMR out-
comes in immediate and staged CR may have been even
greater if both groups were scanned at the same timepoint.
However, it was important that the CMR was performed
after the staged non-IRA procedures to ensure that we
captured associated type 4a MI in our results. Finally, as it
was not routinely captured, we could not confirm whether
the higher incidence of no-reflow in the staged patients was
reflected in less ST-segment elevation resolution post PPCI.
Conclusions
Patients with staged CR in the CvLPRIT CMR substudy
had more visible thrombus in the IRA, higher SYNTAX
score, more stents inserted, higher incidence of no-flow
and subsequently larger infarct size and reduced ejection
fraction, that persisted after correction for important
confounders, than patients treated with immediate CR.
Prospective randomized trials are needed to assess
whether immediate CR results in better clinical out-
comes than staged CR.
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